Database→MK-677 (Ibutamoren)
Tier 2HormonalAnti-agingMetabolicPREMIUM

MK-677 (Ibutamoren)

MK-677 / Ibutamoren Mesylate / LUM-201 (Lumos Pharma) — Non-Peptide GHS-R1a Agonist
Not FDA-approved for any indication. Investigational New Drug (IND) in the United States. No approved products globally as of March 2026. Original Merck development (MK-677) discontinued circa 1999 after mixed Phase 3 pediatric GHD results. Compound relicensed to Lumos Pharma as LUM-201 for pediatric GHD. Phase 2 OraGrowtH210 and OraGrowtH212 trials met all primary and secondary endpoints (November 2023). Phase 3 OraGrowtH trial (NCT06948214) actively enrolling as of 2025. FDA lists ibutamoren as posing significant safety risks due to potential for congestive heart failure. DoD Prohibited Dietary Supplement Ingredients List. WADA prohibited at all times (GH secretagogues). Illegal as dietary supplement ingredient in the US.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

MK-677 (ibutamoren mesylate) is a non-peptide, orally active agonist of the ghrelin receptor (GHS-R1a) that stimulates endogenous GH and IGF-1 secretion. It is the only oral GH secretagogue with substantial published human trial data, including a 2-year, double-blind, placebo-controlled RCT (Nass et al. 2008, Annals of Internal Medicine, n=65). That trial showed significant FFM preservation and GH axis restoration in older adults, with meaningful metabolic liabilities: worsened insulin sensitivity, increased fasting glucose, and no functional strength improvement. A Phase 2b hip fracture trial (Adunsky 2011, n=123) was terminated early for a congestive heart failure signal. An Alzheimer's disease trial (Sevigny 2008, n=563) showed zero cognitive benefit despite a 72.9% IGF-1 increase. The same molecule is now in Phase 3 pediatric GHD development as LUM-201 (Lumos Pharma), with Phase 2 data showing 8.2 cm/yr height velocity comparable to rhGH.

🔒

Full Profile: Premium Members Only

The complete MK-677 (Ibutamoren) profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use